EAM
HAE icon

EULAV Asset Management’s Haemonetics HAE Stock Holding History

EULAV Asset Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-11,500
Closed -$1.15M – 308
2018
Q4 		$1.15M Hold
11,500
– – 0.06% 222
2018
Q3 		$1.32M Hold
11,500
– – 0.06% 222
2018
Q2 		$1.03M Hold
11,500
– – 0.05% 232
2018
Q1 		$841K Buy
+11,500
New +$789K 0.04% 239

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

EULAV Asset Management's HAE Position: Q1 2019 in Review

EULAV Asset Management sold out of Haemonetics (HAE) in Q1 2019, closing a stake of 11,500 shares — an estimated $1.15M sold.

EULAV Asset Management first reported a position in HAE in Q1 2018 and held it in 4 quarters. The position peaked at $1.32M in Q3 2018. 260 funds tracked by Wall St. Rank hold HAE as of Q1 2019.

  • EULAV Asset Management reported no remaining Haemonetics position as of Q1 2019 after selling out during the quarter.
  • EULAV Asset Management sold 11,500 Haemonetics shares in Q1 2019, an estimated $1.15M.
  • EULAV Asset Management first reported a position in Haemonetics in Q1 2018 and held it in 4 quarters.
  • EULAV Asset Management's Haemonetics position peaked at $1.32M in Q3 2018.
  • 260 funds tracked by Wall St. Rank held Haemonetics as of Q1 2019.

Based on EULAV Asset Management's 13F filing for Q1 2019, filed 13 May 2019.